BioCryst Pharmaceuticals | BCRX - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Chugai Pharma JPY 258.74B 25.81B 2025-12
Daiichi Sankyo JPY 439.83B 95.05B 2025-12
DBV Technologies USD 2.77M 33.21M 2025-09
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Gilead Sciences USD 5.52B 791M 2026-03
GlaxoSmithKline GBP 5.75B 429M 2026-03
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Incyte USD 1.17B 217.51M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
Karyopharm Therapeutics USD 32.6M 63.38M 2025-12
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novavax USD 125.04M 76.09M 2025-12
PTC Therapeutics USD 232.94M 84.56M 2026-03
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
Ultragenyx Pharmaceutical USD 106M 72M 2026-03
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03